Journal
CELL REPORTS
Volume 26, Issue 2, Pages 469-+Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2018.12.043
Keywords
-
Categories
Funding
- American Cancer Society [RSG-15-145-01-CDD]
- Cancer Prevention Research Institute of Texas (CPRIT) [RP140612]
- CPRIT [RP130397]
- NIH [1S10OD012304-01, CDP SPORE P50CA127001-07]
- NIH/NCI [P30CA016672]
Ask authors/readers for more resources
The plasticity of a preexisting regulatory circuit compromises the effectiveness of targeted therapies, and leveraging genetic vulnerabilities in cancer cells may overcome such adaptations. Hereditary leiomyomatosis renal cell carcinoma (HLRCC) is characterized by oxidative phosphorylation (OXPHOS) deficiency caused by fumarate hydratase (FH) nullizyogosity. To identify metabolic genes that are synthetically lethal with OXPHOS deficiency, we conducted a genetic loss-of-function screen and found that phosphogluconate dehydrogenase (PGD) inhibition robustly blocks the proliferation of FH mutant cancer cells both in vitro and in vivo. Mechanistically, PGD inhibition blocks glycolysis, suppresses reductive carboxylation of glutamine, and increases the NADP(+)/NADPH ratio to disrupt redox homeostasis. Furthermore, in the OXPHOS-proficient context, blocking OXPHOS using the small-molecule inhibitor IACS-010759 enhances sensitivity to PGD inhibition in vitro and in vivo. Together, our study reveals a dependency on PGD in OXPHOS-deficient tumors that might inform therapeutic intervention in specific patient populations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available